125 related articles for article (PubMed ID: 36350970)
1. Validation of the online PREDICT tool in a cohort of early breast cancer in Brazil.
Magário MB; Santos RRD; Teixeira LA; Tiezzi DG; Pimentel FF; Carrara HHA; Andrade JM; Reis FJCD
Braz J Med Biol Res; 2022; 55():e12109. PubMed ID: 36350970
[TBL] [Abstract][Full Text] [Related]
2. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
van Maaren MC; van Steenbeek CD; Pharoah PDP; Witteveen A; Sonke GS; Strobbe LJA; Poortmans PMP; Siesling S
Eur J Cancer; 2017 Nov; 86():364-372. PubMed ID: 29100191
[TBL] [Abstract][Full Text] [Related]
3. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Wang Y; Broeks A; Giardiello D; Hauptmann M; Jóźwiak K; Koop EA; Opdam M; Siesling S; Sonke GS; Stathonikos N; Ter Hoeve ND; van der Wall E; van Deurzen CHM; van Diest PJ; Voogd AC; Vreuls W; Linn SC; Dackus GMHE; Schmidt MK
Eur J Cancer; 2023 Dec; 195():113401. PubMed ID: 37925965
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer.
Deng Z; Jones MR; Wolff AC; Visvanathan K
JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37773987
[TBL] [Abstract][Full Text] [Related]
5. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
6. A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age.
Yu J; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
J Transl Med; 2021 Feb; 19(1):75. PubMed ID: 33593381
[TBL] [Abstract][Full Text] [Related]
7. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
8. The predictive accuracy of PREDICT: a personalized decision-making tool for Southeast Asian women with breast cancer.
Wong HS; Subramaniam S; Alias Z; Taib NA; Ho GF; Ng CH; Yip CH; Verkooijen HM; Hartman M; Bhoo-Pathy N
Medicine (Baltimore); 2015 Feb; 94(8):e593. PubMed ID: 25715267
[TBL] [Abstract][Full Text] [Related]
9. Development of a Prognostic App (iCanPredict) to Predict Survival for Chinese Women With Breast Cancer: Retrospective Study.
Ma Z; Huang S; Wu X; Huang Y; Chan SW; Lin Y; Zheng X; Zhu J
J Med Internet Res; 2022 Mar; 24(3):e35768. PubMed ID: 35262503
[TBL] [Abstract][Full Text] [Related]
10. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
12. Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients.
Zaguirre K; Kai M; Kubo M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Morisaki T; Mori H; Oda Y; Chen S; Moriyama T; Shimizu S; Nakamura M
Cancer Med; 2021 Mar; 10(5):1605-1613. PubMed ID: 33452761
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
14. External validation of the PREDICT tool in Spanish women with breast cancer participating in population-based screening programmes.
Aguirre U; García-Gutiérrez S; Romero A; Domingo L; Castells X; Sala M;
J Eval Clin Pract; 2019 Oct; 25(5):873-880. PubMed ID: 30548721
[TBL] [Abstract][Full Text] [Related]
15. Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram.
Kim SY; Cho N; Choi Y; Lee SH; Ha SM; Kim ES; Chang JM; Moon WK
Radiology; 2021 May; 299(2):290-300. PubMed ID: 33754824
[TBL] [Abstract][Full Text] [Related]
16. Does the SORG Algorithm Predict 5-year Survival in Patients with Chondrosarcoma? An External Validation.
Bongers MER; Thio QCBS; Karhade AV; Stor ML; Raskin KA; Lozano Calderon SA; DeLaney TF; Ferrone ML; Schwab JH
Clin Orthop Relat Res; 2019 Oct; 477(10):2296-2303. PubMed ID: 31107338
[TBL] [Abstract][Full Text] [Related]
17. External Validation and Optimization of the SPRING Model for Prediction of Survival After Surgical Treatment of Bone Metastases of the Extremities.
Sørensen MS; Gerds TA; Hindsø K; Petersen MM
Clin Orthop Relat Res; 2018 Aug; 476(8):1591-1599. PubMed ID: 30020148
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study.
van der Plas-Krijgsman WG; Giardiello D; Putter H; Steyerberg EW; Bastiaannet E; Stiggelbout AM; Mooijaart SP; Kroep JR; Portielje JEA; Liefers GJ; de Glas NA
Lancet Healthy Longev; 2021 Nov; 2(11):e704-e711. PubMed ID: 36098027
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors and a Nomogram Predicting Survival in Patients with Breast Ductal Carcinoma in situ with Microinvasion: A Population-Based Study.
Zheng YZ; Qin HB; Li ZZ; Jiang HS; Zhang G; Yang SW; Wang XM; Xu YC; Deng ZH; Liu GW
Clin Epidemiol; 2021; 13():1095-1108. PubMed ID: 34876856
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
